预防腹膜透析失败的策略。 - Suppr

Suppr

超能文献

Strategy for preventing peritoneal dialysis failure.

作者信息

Cancarini G

机构信息

University of Brescia and Division of Nephrology, Spedali Civili, Brescia, Italy.

出版信息

Contrib Nephrol. 2001(131):114-24. doi: 10.1159/000060068.

DOI:10.1159/000060068

PMID:11125557

Abstract

摘要

相似文献

Strategy for preventing peritoneal dialysis failure.

Contrib Nephrol. 2001(131):114-24. doi: 10.1159/000060068.

A peritoneal dialysis solution prepared from a three-compartment bag: biological and clinical effects.

Contrib Nephrol. 2001(131):97-106. doi: 10.1159/000060067.

The dialytic failure of the peritoneal membrane.

Contrib Nephrol. 2001(131):90-6. doi: 10.1159/000060066.

Ten years after MIDAS: icodextrin lights and shadows.

Contrib Nephrol. 2003(140):76-81. doi: 10.1159/000071426.

[Icodextrin as first treatment: reasons to be optimistic].

Nefrologia. 2009;29(2):99-102. doi: 10.3265/Nefrologia.2009.29.2.5243.en.full.

Biocompatibility of icodextrin.

Kidney Int Suppl. 2002 Oct(81):S34-45. doi: 10.1046/j.1523-1755.62.s81.6.x.

Clinical research in peritoneal dialysis.

Contrib Nephrol. 2001(131):125-31. doi: 10.1159/000060069.

What is the role of automated peritoneal dialysis and continuous flow peritoneal dialysis?

Contrib Nephrol. 2003(140):264-71. doi: 10.1159/000071399.

Peritoneal transport in long-term peritoneal dialysis patients and its relation with AGEs.

Contrib Nephrol. 2001(131):74-81. doi: 10.1159/000060062.

Glycation and advanced glycation end-product formation with icodextrin and dextrose.

Perit Dial Int. 1997 Jan-Feb;17(1):52-8.

引用本文的文献

Icodextrin: a review of its use in peritoneal dialysis.

Drugs. 2003;63(19):2079-105. doi: 10.2165/00003495-200363190-00011.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Strategy for preventing peritoneal dialysis failure.

Contrib Nephrol. 2001(131):114-24. doi: 10.1159/000060068.

A peritoneal dialysis solution prepared from a three-compartment bag: biological and clinical effects.

Contrib Nephrol. 2001(131):97-106. doi: 10.1159/000060067.

The dialytic failure of the peritoneal membrane.

Contrib Nephrol. 2001(131):90-6. doi: 10.1159/000060066.

Ten years after MIDAS: icodextrin lights and shadows.

Contrib Nephrol. 2003(140):76-81. doi: 10.1159/000071426.

[Icodextrin as first treatment: reasons to be optimistic].

Nefrologia. 2009;29(2):99-102. doi: 10.3265/Nefrologia.2009.29.2.5243.en.full.

Biocompatibility of icodextrin.

Kidney Int Suppl. 2002 Oct(81):S34-45. doi: 10.1046/j.1523-1755.62.s81.6.x.

Clinical research in peritoneal dialysis.

Contrib Nephrol. 2001(131):125-31. doi: 10.1159/000060069.

What is the role of automated peritoneal dialysis and continuous flow peritoneal dialysis?

Contrib Nephrol. 2003(140):264-71. doi: 10.1159/000071399.

Peritoneal transport in long-term peritoneal dialysis patients and its relation with AGEs.

Contrib Nephrol. 2001(131):74-81. doi: 10.1159/000060062.

Glycation and advanced glycation end-product formation with icodextrin and dextrose.

Perit Dial Int. 1997 Jan-Feb;17(1):52-8.

引用本文的文献

Icodextrin: a review of its use in peritoneal dialysis.

Drugs. 2003;63(19):2079-105. doi: 10.2165/00003495-200363190-00011.